Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling.
Wang H, Hou W, Perera A, Bettler C, Beach JR, Ding X, Li J, Denning MF, Dhanarajan A, Cotler SJ, Joyce C, Yin J, Ahmed F, Roberts LR, Qiu W.
Wang H, et al. Among authors: ding x.
Cell Rep. 2021 Feb 23;34(8):108765. doi: 10.1016/j.celrep.2021.108765.
Cell Rep. 2021.
PMID: 33626345
Free PMC article.